The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large internat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058241/
https://ncbi.nlm.nih.gov/pubmed/30037803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019414
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares